U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute

Natera, Inc. (NASDAQ:NTRA) is among the Best Healthcare Stocks.

On June 1, Reuters reported that the U.S. Supreme Court declined to hear CareDx’s appeal in its false-advertising dispute with Natera, Inc. (NASDAQ:NTRA). It left intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests.

Reuters said the justices declined to review whether the diagnostics company owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx’s AlloSure test. It offered no explanation for the decision.

The report noted that US District Judge Colm Connolly overturned a nearly $45 million jury damages award in 2023 after finding no evidence that  Natera, Inc. (NASDAQ:NTRA)’s statements actually misled customers. It still confirmed the jury’s finding of false advertising. The 3rd U.S. Circuit Court of Appeals later affirmed that ruling.

Pixabay / Public Domian

A Natera spokesperson said the firm was “pleased with the outcome in this case.” CareDx argued that courts should presume deception when advertising is “deliberately false,” but Natera said the appellate court correctly applied the agreed trial instructions.

Natera, Inc. (NASDAQ:NTRA) is a diagnostics company. It works in the discovery, development, and marketing of genetic testing services.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.